Novonesis A/S (NVZMF)

OTCMKTS · Delayed Price · Currency is USD
58.02
+0.13 (0.22%)
Dec 23, 2024, 4:00 PM EST
10.51%
Market Cap 26.43B
Revenue (ttm) 3.26B
Net Income (ttm) 303.00M
Shares Out n/a
EPS (ttm) 1.09
PE Ratio 87.23
Forward PE n/a
Dividend 0.30 (0.50%)
Ex-Dividend Date Aug 30, 2024
Volume 500
Open 58.60
Previous Close 57.89
Day's Range 58.02 - 58.60
52-Week Range 49.89 - 71.52
Beta 0.52
Analysts n/a
Price Target n/a
Earnings Date Feb 26, 2025

About Novonesis

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotto... [Read more]

Sector Materials
Founded 1925
Employees 6,756
Stock Exchange OTCMKTS
Ticker Symbol NVZMF
Full Company Profile

Financial Performance

In 2023, Novonesis's revenue was 17.90 billion, an increase of 1.97% compared to the previous year's 17.55 billion. Earnings were 3.02 billion, a decrease of -17.74%.

Financial numbers in EUR Financial Statements

News

Top 3 global stocks poised for 40% gains by 2025

Goldman Sachs has a list of global stocks it expects will outperform in 2025. In particular, the investment bank is bullish on three names – Novozymes, Kawasaki Heavy Industries, and PetroChina.

20 days ago - Invezz

Novonesis A/S (NVZMF) Q3 2024 Earnings Call Transcript

Novonesis A/S (OTCPK:NVZMF) Q3 2024 Earnings Conference Call November 7, 2024 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Offic...

6 weeks ago - Seeking Alpha

Novonesis: Underperformance In Price, But Now I'm Buying (Rating Upgrade)

Novonesis, formed from Chr. Hansen and Novozymes, shows promising growth but remains overvalued with a current P/E of 33x. Find out why I rate NVZMF stock a buy.

6 weeks ago - Seeking Alpha

Novozymes A/S (NVZMF) Q2 2024 Earnings Call Transcript

Novozymes A/S (OTCPK:NVZMF) Q2 2024 Results Conference Call August 28, 2024 3:00 AM ETCompany ParticipantsTobias Björklund - Head of Investor RelationsEster...

4 months ago - Seeking Alpha

Novozymes A/S reports 1H results

4 months ago - Seeking Alpha

Invitation to an extraordinary shareholders' meeting of Novozymes A/S

An extraordinary shareholders' meeting of Novozymes A/S will be held on  Monday March 4, 2024 at 4:00 pm CET at Boege Alle 10-12, 2970 Hoersholm, Denmark.

11 months ago - GlobeNewsWire

The Novozymes Report 2023

This annual report has been released subsequent to the approval of the combination of Novozymes and Chr. Hansen on January 29, 2024.

11 months ago - GlobeNewsWire

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed

Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024 Company announcement No.

11 months ago - GlobeNewsWire

Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript

Novozymes A/S (NVZMF) Q4 2023 Earnings Call Transcript

11 months ago - Seeking Alpha

Legacy Novozymes delivers solid last full-year results

Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last...

11 months ago - GlobeNewsWire

Completion of the combination between Novozymes and Chr. Hansen

January 29, 2024 – Company announcement no. 2 Please see attachment.

11 months ago - GlobeNewsWire

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for b...

11 months ago - GlobeNewsWire

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen

January 26, 2024 – Company announcement no. 1 Please see attachment.

11 months ago - GlobeNewsWire

Novozymes CEO is confident its merger with Chr. Hansen will close in Q1

Novozymes CEO Ester Baiget discusses the Danish biotechnology company's planned combination with with fellow biotech firm Chr. Hansen.

1 year ago - CNBC International TV

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted

December 20, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com A...

1 year ago - GlobeNewsWire

Novozymes' updated financial calendar

Please read the full announcement in PDF Attachment 2023_61_Updated_financial_calendar

1 year ago - GlobeNewsWire

Novozymes and Chr. Hansen announce name of future combined company; Novonesis

Novozymes and Chr. Hansen have announced that the name of the future combined company will be ‘Novonesis'. Novonesis means ‘A new beginning' and derives from the Greek word ‘genesis'. The name reflect...

1 year ago - GlobeNewsWire

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained

December 12, 2023 Please see attachment. Contact information Investor Relations Disa Tuominen+45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-hansen.com A...

1 year ago - GlobeNewsWire

Exclusive: Novozymes, Chr. Hansen tie-up likely to win EU nod, sources say

Danish food ingredients and enzymes makers Novozymes and Chr. Hansen are expected to secure EU antitrust approval for their all-share $22 billion tie-up based on remedies offered to address competitio...

1 year ago - Reuters

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

November 20, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 dkamc@chr-hansen.com Press Relations Sanne Seyer-Hansen+45 6038 6207 dksash@chr-han...

1 year ago - GlobeNewsWire

Novozymes launches Quara® LowP for renewable diesel feedstock pre-treatment

Novozymes, a global leader in biosolutions, marks a significant milestone in the renewable diesel and SAF (Sustainable Aviation Fuel) industry with the launch of Quara® LowP, an enzymatic solution des...

1 year ago - GlobeNewsWire

Novozymes A/S (NVZMF) Q3 2023 Earnings Call Transcript

Novozymes A/S (OTCPK:NVZMF) Q3 2023 Results Conference Call October 26, 2023 3:00 AM ET Company Participants Tobias Cornelius Björklund - Head, Investor Relations Ester Baiget - Chief Executive Office...

1 year ago - Seeking Alpha

We're 'very pleased' with our results, says Novozymes CEO

Ester Baiget, CEO of Novozymes, discusses the company's third-quarter earnings.

1 year ago - CNBC International TV

Novozymes accelerates growth in Q3 and is on track to deliver on full-year expectations

After the first nine months of the 2023 financial year, Novozymes sees increasing demand for sustainable biosolutions and delivers 5 % organic sales growth. The full-year organic sales growth outlook ...

1 year ago - GlobeNewsWire

Novozymes: Close To Being A Buy Again

Novozymes' stock is declining for almost two years and has lost almost 50% of its previous value. The company reported mediocre half-year results for fiscal 2023. But Novozymes has a wide economic moa...

1 year ago - Seeking Alpha